ISA Pharmaceuticals B.V. is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent virus infections. The company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defense mechanisms towards fighting the disease, either alone or in combination with existing therapies.